Karuna Therapeutics, Inc.

NasdaqGM:KRTX Stok Raporu

Piyasa değeri: US$12.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Karuna Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Karuna Therapeutics CEO'su Bill Meury, Jan2023 tarihinde atandı, in görev süresi 1.17 yıldır. şirketin hisselerinin 0.027% doğrudan sahiptir ve bu hisselerin değeri $ 3.41M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.1 yıl ve 4.3 yıldır.

Anahtar bilgiler

Bill Meury

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi1.2yrs
CEO sahipliği0.03%
Yönetim ortalama görev süresi1.1yrs
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Feb 18

Karuna Therapeutics: Getting Sold Short

Summary Karuna Therapeutics is developing a novel product, KarXT, to treat psychoses related to Alzheimer's and schizophrenia. The product targets muscarinic receptors in an agonist/antagonist combination. Some shareholders are suing to prevent the acquisition of Karuna by Bristol-Myers Squibb. Also, the vote is outstanding. The 10% or so deal spread seems small. While the chance that the deal falls through would be bad for the short-term performance of Karuna, it may be a buying moment considering the imminent release and size of markets. Read the full article on Seeking Alpha
Seeking Alpha • Sep 09

Karuna Therapeutics: This Ship Has Sailed

Summary Karuna produced excellent data from its phase 3 trial. They have a boatload of cash. Speaking of boats, however, this ship has already sailed. Since my last coverage of Karuna Therapeutics, Inc. (KRTX) just over a year back, the stock has nearly tripled after posting strong results from its schizophrenia trial, meeting the primary endpoint of that trial. That was a month back, and even though the company took the opportunity to carry out a massive $600mn secondary, the dilution hasn’t put a dent in public enthusiasm. The stock is still going strong, although it is back down a few notches. From my previous coverage of the company, they were running a 246-patient phase 3 trial called EMERGENT-2, and 3 more phase 3 trials in the EMERGENT series, in their lead candidate KarXT in acutely psychotic patients with a DSM-5 diagnosis of schizophrenia. KarXT is a differentiated antipsychotic molecule that combines muscarinic-agonist xanomeline and muscarinic-antagonist trospium chloride together. While xanomeline works in the CNS, trospium helps avoid undesirable, cholinergic side effects that arise due to the stimulation of muscarinic receptors in peripheral tissues. The FDA has guided that “data from EMERGENT-1 [a phase 2 study], one successful Phase 3 efficacy and safety trial, and additional safety data to meet regulatory requirements would be acceptable to support NDA filing in schizophrenia.” The first two phase 3 studies were supposed to have toplined in early 2022. In August, the company announced positive data from the EMERGENT-2 trial. This was a double blind, placebo controlled trial done entirely in the United States. It enrolled 252 adult patients with a confirmed diagnosis of schizophrenia who were experiencing symptoms of psychosis. The primary endpoint was change from baseline in Positive and Negative Syndrome Scale ((PANSS)) total score, a scale for measuring schizophrenia symptom severity, of KarXT compared to placebo at Week 5. The trial resoundingly met its primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001). The trial also met key secondary endpoints. Data include: 2.9-point reduction in the PANSS positive subscale with KarXT compared to placebo (-6.8 KarXT vs. -3.9 placebo, p<0.0001). 1.8-point reduction in the PANSS negative subscale with KarXT compared to placebo (-3.4 KarXT vs. -1.6 placebo, p=0.0055). 2.2-point reduction in the PANSS negative Marder factor subscale with KarXT compared to placebo (-4.2 KarXT vs. -2.0 placebo, p=0.0022). The PANSS scores are used to measure positive symptoms (e.g., hallucinations or delusions) and negative symptoms (e.g., difficulty enjoying life or withdrawal from others) of schizophrenia. Benefit in the negative symptoms has historically been difficult to achieve. The trial’s Cohen’s d effect size of 0.61 compares well “to that of widely used and multibillion-dollar blockbusters Risperdal and Zyprexa (about a 0.5 effect size),” according to William Blair analysts. The drug was generally well-tolerated with little differentiation from placebo. There was transient increase in heart rate, which subsided as the trial ended. Importantly, KarXT was not associated with known side effects of current treatments. As FierceBiotech noted: The clinical trial studied KarXT, a xanomeline formulation designed to address the problems that led Lilly to give up on the molecule despite generating evidence of efficacy. Lilly found the M1 agonist improved cognition in Alzheimer’s disease patients in the 1990s, only for tolerability to stop the program. Karuna sought to address the tolerability problems by giving xanomeline with a peripherally restricted molecule that blocks receptors at the root of the issues without crossing the blood-brain barrier to limit efficacy.
Seeking Alpha • Aug 08

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

Karuna Therapeutics press release (NASDAQ:KRTX): Q2 GAAP EPS of -$2.17 misses by $0.10. Revenue of $5.28M. The Company ended the quarter with $407.4 million in cash, cash equivalents and available-for-sale investment securities compared to $494.0 million as of December 31, 2021. The Company expects that current cash, cash equivalents and available-for-sale investment securities as of June 30, 2022 will enable the Company to fund its operating expenses and capital expenditure requirements for at least 12 months following the potential NDA submission of KarXT for the treatment of psychosis in adults with schizophrenia. Shares +8.29% PM.
Seeking Alpha • Jun 26

Karuna Therapeutics: Front-Running KarXT Phase 3

Treatments for schizophrenia – a truly complex disease--are plagued with a high late-stage trial failure rate. Phase 3 KarXT results will be released this quarter. It will be a binary event. Despite cash balance issues and new clinical stage competitors, market  indicators suggest that investors are re-engaged.

CEO

Bill Meury (55 yo)

1.2yrs
Görev süresi

Mr. William Meury, also known as Bill, served as a Partner at Hildred Capital Management LLC. He serves as Director at Crown Laboratories Inc and serves as its Chairman of the Board of Directors. He curren...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Andrew Miller
Founder and President of Research & Developmentno dataUS$5.77m0.037%
$ 4.6m
Stephen Brannan
Chief Medical Officer7yrsUS$4.41m0.095%
$ 11.9m
William Meury
President1.2yrsVeri yok0.027%
$ 3.4m
Jason Brown
Chief Financial Officerless than a yearVeri yok0.037%
$ 4.6m
Alexis Smith
Vice President of Corporate Affairs & Investor Relationsno dataVeri yokVeri yok
Mia Kelley
General Counsel4.2yrsVeri yokVeri yok
Frank Truslow
Senior Vice President of Corporate Developmentless than a yearVeri yokVeri yok
Jonathan Rosin
Chief Human Resources Officerless than a yearVeri yokVeri yok
Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisorno dataVeri yokVeri yok
Ronald Marcus
Senior Vice President of Medical3.2yrsVeri yokVeri yok
William Kane
Chief Commercial Officer1.1yrsVeri yok0.013%
$ 1.6m
1.1yrs
Ortalama Görev Süresi
57.5yo
Ortalama Yaş

Deneyimli Yönetim: KRTX 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
William Meury
President1.2yrsVeri yok0.027%
$ 3.4m
Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisorno dataVeri yokVeri yok
James Healy
Independent Director4.8yrsUS$336.10k0.085%
$ 10.7m
Jeffrey Jonas
Director5.4yrsUS$326.60k0%
$ 0
Edmund Harrigan
Member of Scientific Advisory Board3.3yrsUS$701.26kVeri yok
Christopher Coughlin
Chairman3.9yrsUS$373.15k0%
$ 0
Steven Paul
Director & Member of Scientific Advisory Board6yrsUS$11.22m0.37%
$ 47.0m
Allan Levey
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Atul Pande
Independent Director & Member of Scientific Advisory Board4.8yrsUS$344.60k0%
$ 0
William Potter
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Laurie Olson
Independent Director3.6yrsUS$345.10k0%
$ 0
Richard Keefe
Member of Scientific Advisory Boardno dataVeri yokVeri yok
4.3yrs
Ortalama Görev Süresi
69yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: KRTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2024/03/18 21:49
Gün Sonu Hisse Fiyatı2024/03/15 00:00
Kazançlar2023/12/31
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Karuna Therapeutics, Inc. 17 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Caroline PalomequeBerenberg
Esther Lannie HongBerenberg
Jason Matthew GerberryBofA Global Research